Investors rotating into cheaper stocks with more upside should ultimately benefit Rocket Lab and AST SpaceMobile. Both have already suffered major drawdowns. x.com 

Rocket Lab's addition to the Nasdaq 100, coming alongside the SpaceX IPO, is set to drive a massive gain in the shares. x.com 

Rocket Lab's fundamentals do not yet justify buying, even after a 55% drop took it to around its 200-day moving average. It still lacks positive earnings, net income and growing free cash flow. The upside could be significant if the business executes over the next few years, but more proof of profitability is needed first; it stays on the watch list. x.com  x.com 

Rocket Lab is a great company worth owning at a discount, and its elevated volatility pays well to wait for one. It is the only US public rocket company at scale, its backlog grows every quarter and revenue is up 55% year over year. Its implied volatility is among the highest in the space sector, with IV rank above 60%, while weekly EMA clouds are green and daily RSI just hit 44. x.com 

Good SpaceX earnings could help Rocket Lab lead the new-space sector higher with a rally as violent as its capitulation. Rocket Lab is the sector leader outside SpaceX; its RSI is extremely oversold, the lower Bollinger band is overstretched and MACD's negative divergence is subsiding. Three upside gaps lie at $55.25-59.18, $64.22-65.71 and $73.11-74.76. The highest should fill before year-end, though the exact date is hard to predict. x.com  x.com 

Rocket Lab has no reason to climb back above $100 anytime soon without a huge catalyst. Earnings were OK but nothing to rave about, and Neutron was delayed. x.com 

Rocket Lab's bounce has room to run to $65 after buyers returned following shipment of Neutron's second stage to its Virginia launch site. A break above $65 before November 9 results remains the real test. x.com 

Rocket Lab has legitimate buying behind it, visible in weekly volume, and could take out $100 this time, perhaps after a pullback, helped by the SpaceX IPO pump. Prior highs around $98-100 are the resistance to clear. x.com 

Rocket Lab still looks ridiculously expensive at 29 times forward sales against SpaceX at 22 times, even after a 65% fall. At 22 times, Rocket Lab would be roughly $38, and SpaceX would still be the pick. SpaceX also has better forward guidance; Rocket Lab's negative adjusted EBITDA makes sales multiples the valuation yardstick. x.com  x.com  x.com  x.com 

Rocket Lab is a better play than the SpaceX IPO, partly because of its lower launch costs. The stock offers a good entry point off its rising 50-day moving average. x.com